Sage Mountain Advisors LLC boosted its stake in  Merck & Co., Inc. (NYSE:MRK – Get Rating) by 6.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 8,437 shares of the company’s stock after purchasing an additional 534 shares during the quarter. Sage Mountain Advisors LLC’s holdings in Merck & Co., Inc. were worth $936,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Tradewinds Capital Management LLC grew its holdings in shares of  Merck & Co., Inc. by 41.5% in the fourth quarter. Tradewinds Capital Management LLC now owns 317 shares of the company’s stock valued at $35,000 after purchasing an additional 93 shares in the last quarter.  Mcrae Capital Management Inc. lifted its stake in  Merck & Co., Inc. by 1.0% in the fourth quarter. Mcrae Capital Management Inc. now owns 9,524 shares of the company’s stock worth $1,057,000 after acquiring an additional 94 shares during the last quarter.  Capital Advantage Inc. lifted its stake in  Merck & Co., Inc. by 0.7% in the fourth quarter. Capital Advantage Inc. now owns 14,353 shares of the company’s stock worth $1,592,000 after acquiring an additional 95 shares during the last quarter.  Arbor Trust Wealth Advisors LLC lifted its stake in  Merck & Co., Inc. by 1.9% in the fourth quarter. Arbor Trust Wealth Advisors LLC now owns 5,106 shares of the company’s stock worth $570,000 after acquiring an additional 95 shares during the last quarter.  Finally, ICA Group Wealth Management LLC lifted its stake in  Merck & Co., Inc. by 0.7% in the third quarter. ICA Group Wealth Management LLC now owns 14,251 shares of the company’s stock worth $1,227,000 after acquiring an additional 99 shares during the last quarter. Institutional investors and hedge funds own  72.89% of the company’s stock.

Several brokerages have recently weighed in on MRK. Cowen boosted their price objective on shares of Merck & Co., Inc. from $108.00 to $120.00 in a research report on Tuesday, January 3rd. Societe Generale downgraded shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Tuesday, March 28th. Wells Fargo & Company downgraded shares of Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $120.00 to $115.00 in a research report on Monday, March 13th. BTIG Research downgraded shares of Merck & Co., Inc. from a “buy” rating to a “neutral” rating in a research report on Sunday. Finally, Wolfe Research upgraded shares of Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $127.00 price objective for the company in a research report on Wednesday, February 22nd. Seven research analysts have rated the stock with a hold rating and seventeen have assigned  a buy rating to the company. Based on data from MarketBeat, the stock  has a consensus rating of “Moderate Buy” and an average target price of $120.65.

In related news, insider Sanat Chattopadhyay sold 134,055 shares of the business’s stock in a transaction dated Thursday, April 13th. The shares were sold at an average price of $115.07, for a total value of $15,425,708.85. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other Merck & Co., Inc. news, EVP Steven Mizell sold 4,436 shares of the company’s stock in a transaction dated Monday, February 6th. The shares were sold at an average price of $104.25, for a total value of $462,453.00. Following the transaction, the executive vice president now directly owns 39,900 shares in the company, valued at approximately $4,159,575. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Sanat Chattopadhyay sold 134,055 shares of the company’s stock in a transaction dated Thursday, April 13th. The shares were sold at an average price of $115.07, for a total transaction of $15,425,708.85. The disclosure for this sale can be found here. Insiders have sold 150,306 shares of company stock worth $17,162,278 in the last three months. Corporate insiders own  0.29% of the company’s stock.

NYSE:MRK opened at $114.83 on Wednesday. The company has a quick ratio of 1.23, a current ratio of 1.47 and a debt-to-equity ratio of 0.62. Merck & Co., Inc. has a fifty-two week low of $83.05 and a fifty-two week high of $116.44. The stock has a market cap of $291.51 billion, a PE ratio of 20.11, a price-to-earnings-growth ratio of 2.09 and a beta of 0.34. The firm’s fifty day simple moving average is $108.50 and its 200-day simple moving average is $105.70.

Merck & Co., Inc. (NYSE:MRK – Get Rating) last posted its quarterly earnings results on Thursday, February 2nd. The company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.56 by $0.06. Merck & Co., Inc. had a net margin of 24.49% and a return on equity of 43.47%. The business had revenue of $13.83 billion for the quarter, compared to analysts’ expectations of $13.66 billion. During the same period in the prior year, the company posted $1.80 EPS. The business’s revenue for the quarter was up 2.3% on a year-over-year basis.  Analysts expect that  Merck & Co., Inc. will post 6.88 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 10th. Investors of record on Wednesday, March 15th were given a $0.73 dividend. The ex-dividend date  was Tuesday, March 14th. This represents a $2.92 annualized dividend and a dividend yield of 2.54%. Merck & Co., Inc.’s dividend payout ratio  is presently 51.14%.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Get Rating).

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.